Agios Pharmaceuticals Shares Surge on Strong Aqvesme Launch and Q1 Growth

Agios Pharmaceuticals (NASDAQ: AGIO) experienced a significant weekly gain of 11.2%, returning the stock to positive territory for the year. The rally was driven by a strong first-quarter performance and the initial commercial success of its latest offering, Aqvesme. The company reported a substantial increase in quarterly revenue, which rose to $20.7 million compared to $8.7 million in the same period last year. This growth is primarily attributed to the first full quarter of sales for Aqvesme, which is approved for the treatment of adult thalassemia. Management indicated that demand for the drug is expected to remain very strong in the coming quarters. Despite the earnings beat, the company faces challenges in the sickle cell disease (SCD) space. Trial results from Novo Nordisk indicated that its drug, etavopivat, outperformed Agios' mitapivat, which failed to meet a primary endpoint regarding the reduction of annualized pain crisis events. Nevertheless, Agios remains in alignment with the FDA for a path toward accelerated approval for mitapivat in SCD, with a filing expected in the second quarter. Investors are now focusing on the company's next-generation PKR activator, tebapivat. Management has confirmed that Phase 2 top-line results for tebapivat in Lower-Risk Myelodysplastic Syndromes (MDS) are expected in the first half of 2026, followed by SCD results in the second half of the year.